Singapore, Sept 6, 2012 - (ACN Newswire) - Scientists from A*STAR’s Singapore Institute for Clinical Sciences (SICS), together with clinical collaborators from London(1), discovered for the first time that children and young patients with chronic Hepatitis B Virus infection (HBV carriers) do have a protective immune response, contrary to current belief, and hence can be more suitable treatment candidates than previously considered.
